News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Stocks in Turmoil, but Attractive Setups Emerge (META, GOOGL, AMZN)
Finviz·2026/03/03 20:18
C3.ai Shares Up 20% Since Monday's Open After Earnings Slide
Finviz·2026/03/03 20:15
BC-OILS
101 finance·2026/03/03 20:12
The Charts of the Week (March 3, 2026)
101 finance·2026/03/03 20:12
Analog Devices and the Macro Cycle: Industrial Upturn Meets Data Center Demand
101 finance·2026/03/03 20:09
“特朗普交易”热度仍在，但还能持续多久?
moomoo-证劵·2026/03/03 20:03
Buffett’s Last Portfolio: A Value Investor Examines the Apple Divestment and Domino’s Investment
101 finance·2026/03/03 20:03
BNB Chain Rolls Out Production-Ready AI Agent Tools With Live On-Chain Capabilities
Newsbtc·2026/03/03 20:03
Utility Shares and the Pressure on Returns
101 finance·2026/03/03 20:00
Flash
22:12
All three major U.S. stock indexes closed lower, while U.S. cybersecurity stocks strengthened.格隆汇 March 6｜The three major US stock indexes closed down collectively, with the Dow Jones falling 1.61%, the S&P 500 index down 0.57%, and the Nasdaq down 0.26%. Major technology stocks were mixed, with Microsoft rising over 1%, Nvidia, Netflix, Amazon, and Intel posting slight gains; Meta fell over 1%, while Apple, Tesla, and Google saw slight declines. US cybersecurity stocks strengthened, with Okta up 11%, CrowdStrike up over 4%, and Datadog up over 3%.
22:08
Simon Property Group announces completion of amendments, restatements, and extensions to existing credit arrangementsThe latest maturity date for this financing instrument has been set for June 30, 2030. It is worth noting that the agreement includes an optional renewal clause, allowing the company to further extend the term to June 30, 2031.
22:07
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan.The company plans to publicly offer its Class A common stock through the underwriter Leerink Partners, with a maximum fundraising scale of up to 100 million USD. This financing plan aims to provide funding support for the company's clinical-stage research and development projects, further advancing the development process of its drugs for the treatment of neurological diseases. Specific issuance terms, including the offering price, number of shares, and final fundraising scale, will be determined based on market conditions.